Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice.
Ki67
chemotherapy
neuroendocrine carcinoma
neuroendocrine neoplasia
neuroendocrine tumor G3
prognosis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 May 2022
31 May 2022
Historique:
received:
19
04
2022
revised:
20
05
2022
accepted:
25
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
Neuroendocrine neoplasia grade 3 (NEN G3) represents a rare and heterogeneous cancer type with a poor prognosis. The aim of our study was to analyze real-world data from the German NET Registry with a focus on therapeutic and prognostic aspects. NEN G3 patients were identified within the German NET Registry. Demographic data and data on treatments and outcomes were retrieved. Univariate analyses were performed using the Kaplan-Meier-method. Multivariate analysis was performed using a Cox proportional hazard model. Of 445 included patients, 318 (71.5%) were diagnosed at stage IV. Well-differentiated morphology (NET G3) was described in 31.7%, 60% of cases were classified as neuroendocrine carcinoma (NEC), and the median Ki67 value was 50%. First-line treatment comprised chemotherapy in 43.8%, with differences in the choice of regimen with regard to NET or NEC, and surgery in 41.6% of patients. Median overall survival for the entire cohort was 31 months. Stage, performance status and Ki67 were significant prognostic factors in multivariate analysis. The survival data of our national registry compare favorably to population-based data, probably mainly because of a relatively low median Ki67 of 50%. Nevertheless, the best first- and second-line approaches for specific subgroups remain unclear, and an international effort to fill these gaps is needed.
Sections du résumé
BACKGROUND
BACKGROUND
Neuroendocrine neoplasia grade 3 (NEN G3) represents a rare and heterogeneous cancer type with a poor prognosis. The aim of our study was to analyze real-world data from the German NET Registry with a focus on therapeutic and prognostic aspects.
METHODS
METHODS
NEN G3 patients were identified within the German NET Registry. Demographic data and data on treatments and outcomes were retrieved. Univariate analyses were performed using the Kaplan-Meier-method. Multivariate analysis was performed using a Cox proportional hazard model.
RESULTS
RESULTS
Of 445 included patients, 318 (71.5%) were diagnosed at stage IV. Well-differentiated morphology (NET G3) was described in 31.7%, 60% of cases were classified as neuroendocrine carcinoma (NEC), and the median Ki67 value was 50%. First-line treatment comprised chemotherapy in 43.8%, with differences in the choice of regimen with regard to NET or NEC, and surgery in 41.6% of patients. Median overall survival for the entire cohort was 31 months. Stage, performance status and Ki67 were significant prognostic factors in multivariate analysis.
CONCLUSIONS
CONCLUSIONS
The survival data of our national registry compare favorably to population-based data, probably mainly because of a relatively low median Ki67 of 50%. Nevertheless, the best first- and second-line approaches for specific subgroups remain unclear, and an international effort to fill these gaps is needed.
Identifiants
pubmed: 35681701
pii: cancers14112718
doi: 10.3390/cancers14112718
pmc: PMC9179270
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Surg Oncol. 2019 May;26(5):1385-1393
pubmed: 30863939
Ann Oncol. 2020 Jul;31(7):844-860
pubmed: 32272208
Pancreas. 2010 Aug;39(6):799-800
pubmed: 20664477
Endocr Relat Cancer. 2013 Aug 19;20(5):649-57
pubmed: 23845449
Oncologist. 2019 Jul;24(7):911-920
pubmed: 30482824
Mod Pathol. 2017 Apr;30(4):587-598
pubmed: 28059098
Cancer Sci. 2014 Sep;105(9):1176-81
pubmed: 24975505
Eur J Cancer. 2021 Jul;152:100-115
pubmed: 34090142
Eur J Gynaecol Oncol. 2017;38(3):418-424
pubmed: 29693884
Oncology. 2017;93(3):177-182
pubmed: 28521313
Endocr Relat Cancer. 2012 Nov 06;19(6):751-7
pubmed: 22940375
Ann Oncol. 2013 Jan;24(1):152-60
pubmed: 22967994
Cancer. 1991 Jul 15;68(2):227-32
pubmed: 1712661
Neuroendocrinology. 2017;104(1):85-93
pubmed: 26943788
Z Gastroenterol. 2018 Oct;56(10):1237-1246
pubmed: 30304748
Pancreas. 2020 Jan;49(1):1-33
pubmed: 31856076
Pancreas. 2020 Apr;49(4):529-533
pubmed: 32282766
Am J Surg. 2020 Aug;220(2):284-289
pubmed: 32209239
Pancreas. 2017 Mar;46(3):302-305
pubmed: 28099254
Eur J Cancer. 2017 Jul;79:158-165
pubmed: 28501762
ScientificWorldJournal. 2012;2012:170496
pubmed: 22973169
Oncologist. 2018 Apr;23(4):422-432
pubmed: 29330208
Neuroendocrinology. 2021;111(9):883-894
pubmed: 33002892
Mod Pathol. 2019 Jul;32(8):1106-1122
pubmed: 30923345
J Endocrinol Invest. 2012 Oct;35(9):817-23
pubmed: 22080849
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):262-277
pubmed: 28894897
Z Gastroenterol. 2018 Jun;56(6):583-681
pubmed: 29890561
Am J Surg Pathol. 2016 Sep;40(9):1192-202
pubmed: 27259015
Cancers (Basel). 2021 Feb 05;13(4):
pubmed: 33562726
Clin Cancer Res. 2016 Feb 15;22(4):1011-7
pubmed: 26482044
Cancer Biomark. 2016;16(3):415-23
pubmed: 27062698
Clin Exp Metastasis. 2005;22(1):25-30
pubmed: 16132575
Digestion. 2017;95(2):109-114
pubmed: 28161703
Neuroendocrinology. 2020;110(7-8):616-629
pubmed: 31557757
Endocr Relat Cancer. 2021 Nov 11;29(1):1-14
pubmed: 34647903
J Cancer Res Clin Oncol. 2018 Jun;144(6):1155-1163
pubmed: 29602973
Cancer. 2018 Feb 15;124(4):807-815
pubmed: 29211313
J Neuroendocrinol. 2021 May;33(5):e12967
pubmed: 33769624
Endocr Relat Cancer. 2015 Feb;22(1):35-45
pubmed: 25465415
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Cancers (Basel). 2021 Apr 16;13(8):
pubmed: 33923759
Oncologist. 2021 May;26(5):383-388
pubmed: 33496040
Am J Surg Pathol. 2012 Apr;36(4):601-11
pubmed: 22314183
Clin Cancer Res. 2017 Aug 15;23(16):4625-4632
pubmed: 28455360
J Nucl Med. 2019 Mar;60(3):377-385
pubmed: 30115686
Cancer. 2011 Oct 15;117(20):4617-22
pubmed: 21456005
Eur J Surg Oncol. 2016 Oct;42(10):1471-7
pubmed: 27528467
Endocr Relat Cancer. 2019 Feb 1;26(2):227-239
pubmed: 30540557
Eur J Surg Oncol. 2017 Sep;43(9):1682-1689
pubmed: 28522174
Endocr Relat Cancer. 2015 Jun;22(3):289-98
pubmed: 25770151
Cancer Med. 2016 Sep;5(9):2261-7
pubmed: 27456539
Endokrynol Pol. 2019;70(4):313-317
pubmed: 30843182
Hum Pathol. 2018 Jul;77:70-79
pubmed: 29596894
Br J Cancer. 1999 Dec;81(8):1351-5
pubmed: 10604732
J Natl Cancer Inst. 2017 Jan 27;109(5):
pubmed: 28130474
Neuroendocrinology. 2009;89(2):217-22
pubmed: 18719344
Neuroendocrinology. 2020;110(3-4):225-233
pubmed: 31079108
Neuroendocrinology. 2018;107(1):24-31
pubmed: 29518779
JAMA Oncol. 2020 Jul 1;6(7):1068-1071
pubmed: 32407439
Neuroendocrinology. 2016;103(2):186-94
pubmed: 26731334
Ann Oncol. 2010 Sep;21(9):1794-1803
pubmed: 20139156
Neuroendocrinology. 2009;90(4):349-63
pubmed: 19776553
Pancreas. 2017 Mar;46(3):296-301
pubmed: 27759713
Cancer Discov. 2016 Jun;6(6):594-600
pubmed: 27048246
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Endocr Relat Cancer. 2015 Aug;22(4):657-64
pubmed: 26113608
Am J Surg Pathol. 2015 May;39(5):683-90
pubmed: 25723112
Tumour Biol. 2016 Jan;37(1):619-25
pubmed: 26240025
Clin Cancer Res. 2020 May 15;26(10):2290-2296
pubmed: 31969335
J Cancer. 2014 Aug 01;5(8):628-32
pubmed: 25157273
Endocr Connect. 2020 Jun;9(6):498-505
pubmed: 32380470
Medicine (Baltimore). 2018 Nov;97(46):e13151
pubmed: 30431587